EPHX2 and metabolic dysfunction-associated steatohepatitis: Recently, it was discovered that sEH inhibition leads to a reduction in hepatic fat accumulation and inflammation, also suggesting a promising role in the treatment of Nonalcoholic Steatohepatitis (NASH) [15,16].